In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.

Market Analysis and Insights: Global Hereditary Angioedema Drug Market
The global Hereditary Angioedema Drug market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Hereditary Angioedema Drug Scope and Market Size
The global Hereditary Angioedema Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Angioedema Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

The Hereditary Angioedema Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Hereditary Angioedema Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.